• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erenumab: from scientific evidence to clinical practice-the first Italian real-life data.

作者信息

Barbanti Piero, Aurilia Cinzia, Egeo Gabriella, Fofi Luisa

机构信息

Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.

San Raffaele University, Rome, Italy.

出版信息

Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.

DOI:10.1007/s10072-019-03839-x
PMID:30927136
Abstract
摘要

相似文献

1
Erenumab: from scientific evidence to clinical practice-the first Italian real-life data.依瑞奈尤单抗：从科学证据到临床实践——意大利的首批真实世界数据
Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.
2
Erenumab: First Global Approval.依瑞奈尤单抗：全球首次获批。
Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.
3
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.意大利中部阿布鲁佐地区依瑞奈umab 的疗效和安全性的真实数据。
J Headache Pain. 2020 Apr 7;21(1):32. doi: 10.1186/s10194-020-01102-9.
4
Erenumab (Aimovig) for Migraine Prophylaxis in Adults.erenumab（Aimovig）用于成人偏头痛的预防。
Am Fam Physician. 2019 Jun 15;99(12):781-782.
5
Medications Approved for Preventing Migraine Headaches.预防偏头痛的药物获批。
Am J Med. 2020 Jun;133(6):664-667. doi: 10.1016/j.amjmed.2020.01.031. Epub 2020 Mar 5.
6
Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).偏头痛预防治疗药物 Aimovig（依瑞奈尤单抗）识别 CGRPR 复合物的分子机制研究
Cell Rep. 2020 Feb 11;30(6):1714-1723.e6. doi: 10.1016/j.celrep.2020.01.029.
7
Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.依瑞奈尤单抗用于预防线粒体脑病、乳酸酸中毒和卒中样发作综合征患者偏头痛：一例报告
Headache. 2021 Apr;61(4):694-696. doi: 10.1111/head.14101. Epub 2021 Mar 29.
8
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.欧洲头痛联合会关于使用作用于降钙素基因相关肽或其受体的单克隆抗体预防偏头痛的指南。
J Headache Pain. 2019 Jan 16;20(1):6. doi: 10.1186/s10194-018-0955-y.
9
Vascular safety of erenumab for migraine prevention.依那西普预防偏头痛的血管安全性。
Neurology. 2020 Feb 4;94(5):e497-e510. doi: 10.1212/WNL.0000000000008743. Epub 2019 Dec 18.
10
CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.降钙素基因相关肽（CGRP）拮抗剂治疗慢性偏头痛：全面综述。
Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.

引用本文的文献

1
Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine.抗降钙素基因相关肽单克隆抗体在≥65岁每日或非每日发作偏头痛患者中的疗效和耐受性
Neurol Clin Pract. 2025 Feb;15(1):e200373. doi: 10.1212/CPJ.0000000000200373. Epub 2024 Oct 8.
2
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.降钙素基因相关肽单克隆抗体：来自真实世界证据的关键经验教训。
Brain Sci. 2024 Sep 22;14(9):948. doi: 10.3390/brainsci14090948.
3
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review.

本文引用的文献

1
CGRP and headache: a brief review.降钙素基因相关肽与头痛：简要综述。
Neurol Sci. 2019 May;40(Suppl 1):99-105. doi: 10.1007/s10072-019-03769-8.
2
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.依瑞奈尤单抗治疗偏头痛预防性治疗的疗效和安全性的系统评价和荟萃分析。
Drugs. 2019 Mar;79(4):417-431. doi: 10.1007/s40265-019-01069-1.
3
Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like.偏头痛的药理学试验：是时候重新评估头痛的部位以及疼痛的性质了。
关于偏头痛 CGRP 通路单克隆抗体的真实世界证据研究的方法学考虑：系统评价。
J Headache Pain. 2023 Jun 22;24(1):75. doi: 10.1186/s10194-023-01611-3.
4
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.在多次预防性治疗失败的偏头痛患者中，氟雷马尼单抗在 24 周内的早期和持续疗效：多中心、前瞻性、真实世界的 FRIEND2 研究。
J Headache Pain. 2023 Mar 23;24(1):30. doi: 10.1186/s10194-023-01561-w.
5
Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.降钙素基因相关肽单克隆抗体作为偏头痛治疗方法的研究进展：一项叙述性综述
Saudi J Med Med Sci. 2023 Jan-Mar;11(1):11-18. doi: 10.4103/sjmms.sjmms_95_22. Epub 2023 Jan 14.
6
Photophobia and migraine outcome during treatment with galcanezumab.加卡奈珠单抗治疗期间的畏光和偏头痛结局
Front Neurol. 2023 Jan 18;13:1088036. doi: 10.3389/fneur.2022.1088036. eCollection 2022.
7
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data.降钙素基因相关肽单克隆抗体治疗偏头痛预防：真实世界数据的系统评价。
Cells. 2022 Dec 29;12(1):143. doi: 10.3390/cells12010143.
8
Assessment and characteristics of Erenumab therapy on migraine management.依瑞奈尤单抗治疗偏头痛的评估及特点
Saudi Pharm J. 2022 Aug;30(8):1153-1158. doi: 10.1016/j.jsps.2022.06.015. Epub 2022 Jun 22.
9
Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.偏头痛靶向治疗的真实世界患者体验：叙事性综述。
Curr Pain Headache Rep. 2022 Oct;26(10):783-794. doi: 10.1007/s11916-022-01077-z. Epub 2022 Sep 5.
10
Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.erenumab预防偏头痛：聚焦患者选择、观点与结果。
Ther Clin Risk Manag. 2022 Apr 5;18:359-378. doi: 10.2147/TCRM.S263825. eCollection 2022.
Headache. 2015 Mar;55(3):439-41. doi: 10.1111/head.12498. Epub 2014 Dec 19.